After hours

Roivant Sciences Ltd. Common Shares

ROIV · Nasdaq

Analyst Consensus

Buy

12 analysts

$35

Current

—

Low

$48

Average

—

High

Average target implies +38.33% versus the current price.

Analyst Ratings Synthesis

A reliable consensus rating and analyst count are unavailable in the supplied evidence. Published target references are inconsistent: TipRanks reports a 12-month average of $42.44, Simply Wall St describes an average near $27, Benzinga cites a maintained range moving from $33.00 to $34.00, and MLQ identifies H.C. Wainwright with a $33.00 target. The evidence therefore suggests a broad published range of roughly $27 to $42.44, but it does not identify the most or least bullish individual analyst. Revisions appear directionally positive, with TD Cowen raising its target and Simply Wall St citing modest increases, while Benzinga reports a maintenance. The substantive disagreement is pipeline value versus current losses and valuation risk.

Rating Actions

No individual rating actions have been captured for ROIV yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

CANTOR FITZGERA

DEUTSCHE BK SEC

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

PIPER SANDLER

TD COWEN

TRUIST SECURITI

Symbol: ROIV
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Country: Europe
Exchange: Nasdaq

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes LISRAYA (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies.

Key Issues

Bullish view

The reported Phase 2 results beat key endpoints, and Seeking Alpha said the stock rose 19% on the data. Supporters argue that successful clinical evidence can create substantial value before revenue is visible.

Bearish view

The evidence does not establish regulatory approval, commercial launch timing, or eventual efficacy beyond the reported trial endpoints. Investors may therefore be capitalizing uncertain clinical data before the asset generates sales.

Analyst Consensus

See all

Buy

12 analysts

$35

Current

—

Low

$48

Average

—

High

Average target implies +38.33% versus the current price.

Earnings History

BeatMissNo estimate

Roivant Sciences Ltd. Common Shares

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers